Gina P Kwon, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kwon’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A137176 · Current
Licensed to practise in California · since 2015 · expires 2027-02-28 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$29,303
Medicare paid this office $29,303 for 207 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 109 | $11,570 | $83 |
| Short return visit (20+ min) | 94 | $5,387 | $48 |
| Destruction of precancer skin growth, 1 growth | 62 | $3,822 | $46 |
| Destruction of skin growth, 1-14 growths | 14 | $1,603 | $59 |
| Biopsy of related skin growth, first growth | 48 | $1,390 | $25 |
See all 8 services
| Return visit (30+ min) | 109 | $11,570 | $83 |
| Short return visit (20+ min) | 94 | $5,387 | $48 |
| Destruction of precancer skin growth, 1 growth | 62 | $3,822 | $46 |
| Destruction of skin growth, 1-14 growths | 14 | $1,603 | $59 |
| Biopsy of related skin growth, first growth | 48 | $1,390 | $25 |
| New patient visit (30+ min) | 18 | $1,383 | $77 |
| Destruction of precancer skin growth, 2-14 growths | 50 | $499 | $2 |
| Biopsy of related skin growth, each additional growth | 12 | $259 | $18 |
Procedures Medicare counted
| Removal of skin lesions | 191 | More than 79% of doctors who do this |
| Skin biopsy | 51 | More than 69% of doctors who do this |
Who their Medicare patients are
207 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 62% · Also on Medicaid 17% · Health risk score 1.09. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 59% · Coronary heart disease 20% · Diabetes 18% · Cancer 17% · Atrial fibrillation 16% · Chronic kidney disease 15% · Depression 13% · Heart failure 12% · COPD 9%.
The office billed $139,910, Medicare allowed $42,293 and paid $29,303; for 810 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 207 | 810 | 75 | 1.09 | $139,910 | $29,303 |
| 2023 | 181 | 766 | 74 | 1.02 | $122,808 | $26,805 |
| 2022 | 139 | 687 | 74 | 1.08 | $101,881 | $22,316 |
| 2021 | 112 | 411 | 73 | 1.17 | $52,181 | $14,265 |
| 2020 | 29 | 62 | 75 | 1.65 | $15,290 | $697 |
| 2019 | 263 | 905 | 71 | 1.41 | $279,673 | $35,886 |
| 2018 | 74 | 204 | 71 | 1.33 | $50,905 | $9,276 |
| 2017 | 144 | 371 | 72 | 1.54 | $87,130 | $15,697 |
| 2016 | 59 | 135 | 74 | 1.36 | $22,367 | $5,583 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 89 | $9,370 | $88 |
| Short return visit (20+ min) | 90 | $6,211 | $55 |
| Destruction of precancer skin growth, 1 growth | 48 | $3,846 | $51 |
| Biopsy of related skin growth, first growth | 46 | $1,226 | $25 |
| New patient visit (30+ min) | 12 | $833 | $69 |
| Destruction of precancer skin growth, 2-14 growths | 42 | $652 | $2 |
| Biopsy of related skin growth, each additional growth | 13 | $283 | $18 |
2022: 6 services
| Return visit (30+ min) | 70 | $7,032 | $83 |
| Short return visit (20+ min) | 72 | $4,842 | $50 |
| Destruction of precancer skin growth, 1 growth | 53 | $3,493 | $49 |
| New patient visit (30+ min) | 24 | $1,674 | $70 |
| Biopsy of related skin growth, first growth | 36 | $1,004 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 46 | $556 | $2 |
2021: 7 services
| Return visit (30+ min) | 40 | $3,632 | $86 |
| Short return visit (20+ min) | 42 | $2,589 | $55 |
| Destruction of precancer skin growth, 1 growth | 33 | $1,855 | $50 |
| New patient visit (45+ min) | 14 | $1,637 | $117 |
| New patient visit (30+ min) | 17 | $1,179 | $69 |
| Biopsy of related skin growth, first growth | 26 | $676 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $384 | $2 |
2020: 1 service
| Return visit (30+ min) | 14 | $324 | $23 |
2019: 10 services
| Return visit (30+ min) | 134 | $13,654 | $74 |
| New patient visit (30+ min) | 49 | $3,806 | $78 |
| Destruction of precancer skin growth, 1 growth | 60 | $3,631 | $46 |
| Biopsy of related skin growth, first growth | 50 | $3,540 | $60 |
| Short return visit (20+ min) | 63 | $3,397 | $45 |
| New patient visit (15+ min) | 49 | $2,563 | $52 |
| Destruction of skin growth, 1-14 growths | 17 | $2,314 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 49 | $1,242 | $4 |
| Punch biopsy, first skin growth | 11 | $820 | $75 |
| Biopsy of related skin growth, each additional growth | 13 | $465 | $36 |
2018: 6 services
| Return visit (30+ min) | 27 | $2,260 | $78 |
| New patient visit (30+ min) | 18 | $1,459 | $81 |
| Biopsy of single growth of skin and/or tissue | 25 | $1,439 | $58 |
| Destruction of precancer skin growth, 1 growth | 16 | $742 | $44 |
| Short return visit (20+ min) | 14 | $668 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $194 | $3 |
2017: 8 services
| New patient visit (30+ min) | 55 | $4,433 | $81 |
| Short return visit (20+ min) | 63 | $3,566 | $49 |
| Biopsy of single growth of skin and/or tissue | 35 | $1,607 | $45 |
| New patient visit (15+ min) | 23 | $1,367 | $59 |
| Destruction of skin growth, 1-14 growths | 17 | $1,353 | $68 |
| Destruction of precancer skin growth, 1 growth | 27 | $1,308 | $42 |
| Short return visit | 13 | $470 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $338 | $4 |
2016: 4 services
| Short return visit (20+ min) | 20 | $1,050 | $50 |
| New patient visit (30+ min) | 13 | $1,011 | $78 |
| Biopsy of single growth of skin and/or tissue | 11 | $672 | $61 |
| Short return visit | 16 | $492 | $31 |
Drugs they prescribed that Part D paid
$26,677
Pharmacies billed $26,677 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 221) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
208 generic and 13 brand-name prescriptions · $26,677 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluorouracil | 21 | $1,985 | $95 |
| Triamcinolone Acetonide | 38 | $473 | $12 |
| Ketoconazole | 36 | $467 | $13 |
| Fluocinonide | 13 | $451 | $35 |
| Clindamycin Phosphate | 12 | $301 | $25 |
See all 7 drugs
| Fluorouracil | 21 | $1,985 | $95 |
| Triamcinolone Acetonide | 38 | $473 | $12 |
| Ketoconazole | 36 | $467 | $13 |
| Fluocinonide | 13 | $451 | $35 |
| Clindamycin Phosphate | 12 | $301 | $25 |
| Hydrocortisone | 20 | $73 | $4 |
| Mupirocin | 12 | $40 | $3 |
Year by year
| 2024 | 221 | 105 | 0% (0) | 6% | $26,677 |
| 2023 | 175 | 74 | 0% (0) | None | $14,392 |
| 2022 | 119 | 52 | 0% (0) | None | $4,778 |
| 2021 | 96 | 50 | 0% (0) | None | $2,351 |
| 2020 | 147 | 44 | 0% (0) | 12% | $163,400 |
| 2019 | 379 | 129 | 0% (0) | 16% | $248,681 |
| 2018 | 222 | 105 | 0% (0) | 20% | $55,009 |
| 2017 | 423 | 152 | 0% (0) | 15% | $64,886 |
| 2016 | 58 | 32 | 0% (0) | None | $2,669 |
| 2015 | 26 | None | 0% (0) | None | $420 |
| 2014 | 15 | None | 0% (0) | None | $3,039 |
| 2013 | 63 | 24 | 0% (0) | None | $6,524 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Ketoconazole | 42 | $880 | $21 |
| Fluorouracil | 14 | $835 | $60 |
| Triamcinolone Acetonide | 37 | $574 | $16 |
| Mupirocin | 17 | $230 | $14 |
| Hydrocortisone | 11 | $50 | $5 |
2022: 2 drugs
| Ketoconazole | 29 | $731 | $25 |
| Triamcinolone Acetonide | 26 | $386 | $15 |
2021: 3 drugs
| Ketoconazole | 19 | $358 | $19 |
| Triamcinolone Acetonide | 20 | $259 | $13 |
| Hydrocortisone | 14 | $81 | $6 |
2020: 3 drugs
| Clindamycin Phosphate | 23 | $539 | $23 |
| Triamcinolone Acetonide | 20 | $482 | $24 |
| Ketoconazole | 31 | $437 | $14 |
2019: 10 drugs
| Cosentyx Pen (2 Pens) | 12 | $63,922 | $5,327 |
| Fluorouracil | 17 | $2,225 | $131 |
| Fluocinonide | 29 | $1,865 | $64 |
| Clobetasol Propionate | 25 | $1,714 | $69 |
| Betamethasone Dipropionate | 18 | $1,655 | $92 |
| Clindamycin Phosphate | 16 | $1,498 | $94 |
| Triamcinolone Acetonide | 69 | $1,386 | $20 |
| Ketoconazole | 57 | $1,022 | $18 |
| Doxycycline Hyclate | 13 | $301 | $23 |
| Hydrocortisone | 29 | $148 | $5 |
2018: 7 drugs
| Fluorouracil | 15 | $3,575 | $238 |
| Betamethasone Diprop Augmented | 12 | $2,058 | $171 |
| Fluocinonide | 21 | $1,870 | $89 |
| Alclometasone Dipropionate | 21 | $1,556 | $74 |
| Triamcinolone Acetonide | 38 | $1,132 | $30 |
| Ketoconazole | 13 | $290 | $22 |
| Mupirocin | 12 | $204 | $17 |
2017: 10 drugs
| Fluorouracil | 15 | $4,363 | $291 |
| Clobetasol Propionate | 20 | $3,411 | $171 |
| Fluocinonide | 34 | $2,877 | $85 |
| Metronidazole | 25 | $2,184 | $87 |
| Ketoconazole | 77 | $2,050 | $27 |
| Alclometasone Dipropionate | 21 | $1,736 | $83 |
| Clindamycin Phosphate | 21 | $1,581 | $75 |
| Triamcinolone Acetonide | 59 | $1,407 | $24 |
| Mupirocin | 18 | $324 | $18 |
| Hydrocortisone | 26 | $216 | $8 |
2016: 1 drug
| Triamcinolone Acetonide | 14 | $267 | $19 |
2015: 1 drug
| Ketoconazole | 17 | $181 | $11 |
2013: 1 drug
| Triamcinolone Acetonide | 11 | $184 | $17 |
Money from drug and device companies
$15 in 2023
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $15 | 1 payment
|
See the published payment
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225263395
- Licence
- CA A137176California A137176: Current · expires 2027-02-28
- Trained
- Stanford University School of Medicine, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St, Pavilion C, Mc 5334, Redwood City, CA, 94063
- NPI first listed
- 2009-05-19
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063